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High cytokeratin 19 fragment/carcinoembryonic antigen ratio is a 
negative predictor of EGFR T790M mutation in EGFR-mutant NSCLC 
patients after EGFR-TKI failure 
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The association between tumor markers, carcinoembryonic antigen (CEA) and cytokeratin 19 
fragments (CYFRA21-1), and T790M point mutation in exon 20 (T790M) status after the 
resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) remains 
unclear. We retrospectively analyzed 126 advanced EGFR-mutant NSCLC patients who were 
subsequently re-biopsied to investigate T790M mutation following resistance to initial 
EGFR-TKIs. Results: Serum CYFRA21-1 level was significantly associated with T790M 
mutation ([<3.5 ng/mL]: 59.7% versus [3.5 ng/mL≦]: 38.8%, P = 0.0217). Moreover, patients 
with high CYFRA21-1/CEA (<0.7) ratio had a significantly lower prevalence of T790M 
mutation than those with low ratio (≧0.7) [25.4% versus 74.6%, P = 0.007]. Multivariate 
analysis showed that high CYFRA21-1/CEA ratio is a negative predictor of T790M mutation 
[odds ratio: 0.226 (95% confidence interval: 0.051–0.834), P = 0.025]. In conclusion, igh 
CYFRA21-1/CEA ratio is a negative predictor of EGFR T790M mutation. 
 
